1. Home
  2. RNA

as 07-01-2025 3:41pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Founded: 2012 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 3.6B IPO Year: 2020
Target Price: $68.00 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 14
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.03 EPS Growth: N/A
52 Week Low/High: $21.51 - $56.00 Next Earning Date: 08-08-2025
Revenue: $8,927,000 Revenue Growth: -17.88%
Revenue Growth (this year): -41.73% Revenue Growth (next year): 156.80%

RNA Daily Stock ML Predictions

Stock Insider Trading Activity of Avidity Biosciences Inc. (RNA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Gallagher Kathleen P. RNA Chief Program Officer Jun 17 '25 Sell $30.24 911 $27,548.64 50,392
Gallagher Kathleen P. RNA Chief Program Officer Jun 2 '25 Sell $32.48 5,875 $190,832.93 50,392
Gallagher Kathleen P. RNA Chief Program Officer May 1 '25 Sell $32.40 5,875 $190,324.15 50,392

Share on Social Networks: